Peptic Ulcer Disease
12
1
1
9
Key Insights
Highlights
Success Rate
90% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
8.3%
1 terminated out of 12 trials
90.0%
+3.5% vs benchmark
17%
2 trials in Phase 3/4
0%
0 of 9 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 9 completed trials
Clinical Trials (12)
Vonoprazan-based Versus Esomeprazole-based Triple Therapy for Helicobacter Pylori Eradication
Predicting Peptic Complications Using H. Pylori Serology and Gastric Ultrasound
Comparative Effectiveness of Triple Versus Quadruple Therapy in the Treatment of Helicobacter Pylori Induced Gastritis
Efficacy and Safety of Hou Gu Mi Xi in Patients With Peptic Ulcer Diseases
Inventory of Inappropriate Prescriptions of Proton Pump Inhibitors (PPIs) in People Over 75 Years of Age
Minimally Invasive Evaluation of Dyspepsia by Combined Magnetically Controlled Capsule Endoscopy and Urea Breath Test: a Pilot Prospective Cohort Study
Frequent Ketamine Use and Gastrointestinal, Liver and Biliary Sequelae
Volatile Markers in Digestive Cancer
Serum Zinc, Peptic Ulcer Disease and H. Pylori Infection
Study Comparing Esomeprazole and ASA Combined Together as One Capsule Versus These Medications Taken Separately
Prognostic Indicators as Provided by the EPIC ClearView
Study Comparing Esomeprazole and Acetylsalicylic Acid (ASA) Combined Together as One Capsule Versus These Medications Taken Separately